Results 271 to 280 of about 484,364 (380)

Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary myocardial disease. Percutaneous endocardial septal radiofrequency ablation (PESA) is an innovative approach for treating HOCM. Consequently, we present the outcomes of the PESA for HOCM. Methods This study included 20 patients with HOCM who received PESA.
NingNing Zheng   +6 more
wiley   +1 more source

Double blind evaluation of dyphylline, theophylline and placebo for exercise induced bronchospasm

open access: bronze, 1982
C FURUKAWA   +4 more
openalex   +1 more source

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano   +8 more
wiley   +1 more source

Lying to win-placebos and sport science.

open access: yesInternational Journal of Sports Physiology and Performance, 2013
S. Halson, David T. Martin
semanticscholar   +1 more source

Population Pharmacokinetic and Exposure‐Response Analysis of the Cognitive Effects of TAK‐071 in Participants With Parkinson Disease and Cognitive Impairment

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract TAK‐071 is a novel muscarinic M1 positive allosteric modulator under investigation for the treatment of cognitive impairment and falls associated with Parkinson disease (PD). This study evaluated population pharmacokinetics of TAK‐071 following single (1‐160 mg) and multiple (3‐15 mg once daily) oral‐dose TAK‐071 in 112 healthy participants ...
Hongxia Jia   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy